Literature DB >> 20556773

Copper containing intra-uterine devices versus depot progestogens for contraception.

G Justus Hofmeyr1, Mandisa Singata, Theresa A Lawrie.   

Abstract

BACKGROUND: Highly effective contraception is essential to reduce unintended pregnancies and the effect these have on individuals, society and public health resources. Intrauterine devices (IUDs) and depot progestogens are two commonly used long-acting, reversible contraceptive methods with different risk and benefit profiles.
OBJECTIVES: To compare the contraceptive and non-contraceptive benefits and risks of using the copper-containing IUD versus depot progestogens for contraception. SEARCH STRATEGY: In June 2009 we searched the Cochrane Pregnancy and Childbirth Group Trials Register, the Cochrane Central Register of Controlled Trials, Pubmed, Popline, Clinical Trials.gov, the Current Controlled Trials metaRegister, EMBASE and LILACS, and contacted study authors. SELECTION CRITERIA: Randomized trials comparing women using copper-containing IUDs with women using depot progestogens. DATA COLLECTION AND ANALYSIS: We assessed eligibility and trial quality, extracted and double-entered data. MAIN
RESULTS: Two studies were included in the review. In the one study in HIV infected women, the IUD was compared with depot progestogen or the oral contraceptive, according to the women's choice. As the majority of women chose depot progestogen, we have included this study in the review, within a mixed hormonal contraception sub-group.Overall, the copper IUD was more effective than depot progestogens/hormonal contraception at preventing pregnancy (risk ratio (RR) 0.45; 95% confidence interval (CI) 0.24 to 0.84). HIV disease progression was reduced in the IUD group (RR 0.58; 95% CI 0.39 to 0.87). There was no significant difference in pelvic inflammatory disease rates between the two groups. Discontinuation of the allocated method was less frequent with the IUD in one study, and less frequent with hormonal contraception in the other study (in which women were allowed to switch between various hormonal methods). AUTHORS'
CONCLUSIONS: In the populations studied, the IUD was more effective than hormonal contraception with respect to pregnancy prevention. High quality research is urgently needed to compare the effects, if any, of these two commonly used contraception methods on HIV acquisition/seroconversion and HIV/AIDS disease progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556773      PMCID: PMC8981912          DOI: 10.1002/14651858.CD007043.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  56 in total

Review 1.  Immediate post-partum insertion of intrauterine devices.

Authors:  D Grimes; K Schulz; H Van Vliet; N Stanwood
Journal:  Cochrane Database Syst Rev       Date:  2003

2.  Reasons and correlates of contraceptive discontinuation in Kuwait.

Authors:  N M Shah; M A Shah; R I Chowdhury; I Menon
Journal:  Eur J Contracept Reprod Health Care       Date:  2007-09       Impact factor: 1.848

3.  Risk factors for IUD failure: results of a large multicentre case-control study.

Authors:  Patrick Thonneau; Thierry Almont; Elise de La Rochebrochard; Bernard Maria
Journal:  Hum Reprod       Date:  2006-06-14       Impact factor: 6.918

4.  Invited commentary: a critical look at some popular meta-analytic methods.

Authors:  S Greenland
Journal:  Am J Epidemiol       Date:  1994-08-01       Impact factor: 4.897

Review 5.  Contraception for the older woman: an update.

Authors:  R K Bhathena; J Guillebaud
Journal:  Climacteric       Date:  2006-08       Impact factor: 3.005

Review 6.  Highly effective contraception and acquisition of HIV and other sexually transmitted infections.

Authors:  Charles S Morrison; Abigail Norris Turner; LaShawn B Jones
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2009-02-10       Impact factor: 5.237

7.  Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen.

Authors:  David Hubacher; Veronica Reyes; Sonia Lillo; Bosny Pierre-Louis; Ana Zepeda; Pai-Lien Chen; Horacio Croxatto
Journal:  Hum Reprod       Date:  2006-02-16       Impact factor: 6.918

8.  Genital tract infections associated with the intrauterine contraceptive device can be reduced by inserting the threads into the uterine cavity.

Authors:  M Pap-Akeson; F Solheim; G Thorbert; M Akerlund
Journal:  Br J Obstet Gynaecol       Date:  1992-08

Review 9.  Copper intrauterine device use by nulliparous women: review of side effects.

Authors:  David Hubacher
Journal:  Contraception       Date:  2007-02-20       Impact factor: 3.375

10.  A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus.

Authors:  Elizabeth M Stringer; Christine Kaseba; Jens Levy; Moses Sinkala; Robert L Goldenberg; Benjamin H Chi; Inutu Matongo; Sten H Vermund; Mulindi Mwanahamuntu; Jeffrey S A Stringer
Journal:  Am J Obstet Gynecol       Date:  2007-08       Impact factor: 8.661

View more
  3 in total

1.  Positive Testing for Neisseria gonorrhoeae and Chlamydia trachomatis and the Risk of Pelvic Inflammatory Disease in IUD Users.

Authors:  Natalia E Birgisson; Qiuhong Zhao; Gina M Secura; Tessa Madden; Jeffrey F Peipert
Journal:  J Womens Health (Larchmt)       Date:  2015-04-02       Impact factor: 2.681

2.  Effects of the copper intrauterine device versus injectable progestin contraception on pregnancy rates and method discontinuation among women attending termination of pregnancy services in South Africa: a pragmatic randomized controlled trial.

Authors:  G Justus Hofmeyr; Mandisa Singata-Madliki; Theresa A Lawrie; Eduardo Bergel; Marleen Temmerman
Journal:  Reprod Health       Date:  2016-04-18       Impact factor: 3.223

3.  Psychological, behavioural and physiological effects of three long-acting reversible contraception (LARC) methods: protocol for an ancillary study of the ECHO randomised trial.

Authors:  Mandisa Singata-Madliki; G Justus Hofmeyr; Florence Carayon-Lefebvre d'Hellencourt; Theresa Anne Lawrie
Journal:  BMJ Open       Date:  2017-11-12       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.